A Collection is a selection of features, articles, comments and opinions on any given theme or topic. It allows you to stay up‑to‑date with what interests you most.
Login here to access your saved articles and followed authors.
We have sent you an email so you can reset your password.
Sorry, we had a problem.
Tags related to this article
Published 8 noviembre 2018
The case related to a middle-aged man who had been diagnosed with sporadic CJD, which is a progressive neurodegenerative condition. His life expectancy was likely to be less than 12 months.
The issue before the court was whether KG should be given a completely new drug (called PRN100), which had never been tested on/given to humans.
Possible adverse side-effects/ reactions were unknown and it was impossible to quantify the chances of the drug bringing any benefit, although there was some evidence from animal studies that it could have a positive effect on the progression of CJD in humans.
Faced with the prospect of no alternative treatment, however, the clinical team, family and KG himself (insofar as he was able to express a view despite lacking capacity) were in unanimous agreement that the drug should be given.
Having weighed up the possible advantages/ disadvantages of this novel treatment and having taken into account the views of KG's family and KG himself (who made clear that he wanted as much time as possible with his family), the judge found that it was 'plainly' in KG's best interests to have the treatment.
Significantly, however, the judge stopped short of agreeing with the Trust's proposal - made in light of the 'Y' decision - not to make further court applications in future cases of possible treatment with this drug where there is no dispute about best interests.
Instead, the judge took a cautious approach and suggested that it '…might be premature to arrive at such a conclusion until the results of this treatment are known. It may be that the benefit or risk analysis changes'.
This case highlights there are still circumstances where - even though there is no dispute about best interests - an application to the Court of Protection is the right way forward because there is doubt about the outcome/effect of what is being proposed - e.g. because the treatment is novel/ untested.
This fits with the MCA Code of Practice (which was described by the Supreme Court in 'Y' as being 'rather ambiguous' about when an application to court should be made), which suggests that decisions involving ethical dilemmas in untested areas such as innovative treatments for CJD are 'likely' to be referred to the court.
As ever, though, whether or not a court application is needed will turn on the particular scenario facing the clinical team.
Our national team of MCA and Court of Protection specialists provide responsive, practical advice on all aspects of the law in this area, including:
+44 (0)191 404 4045
+44 (0)113 251 4763
Helen Kingston, Gill Weatherill, Sarah Woods
Peter Merchant, Louise Wiltshire, Tracey Longfield, Gill Weatherill
Hamza Drabu, Charlotte Burnett, Alistair Robertson, David Hill
Gill Weatherill, Sarah Woods, Paul McGough
Helen Kingston, Sarah Woods, Matthew Nichols
Anna Hart, Louise Watson-Jones, Stan Campbell
Anna Hart, Tracey Longfield, Corinne Slingo, Robyn Reed
Gill Weatherill, Helen Kingston, Sarah Woods, Amy Fishburn
Tracey Longfield, Corinne Slingo, Gill Weatherill
Gill Weatherill, Helen Kingston, Sarah Woods
Corinne Slingo, Anna Hart, Peter Merchant
Tracey Longfield, Colin Moore, Claire Anderson
Peter Merchant, Will Pickles, Sonia Khan
Gill Weatherill, Sarah Woods
Corinne Slingo, Tracey Longfield
Tracey Longfield, Louise Wiltshire, Christian Carr
Tracey Longfield, Gill Weatherill, Corinne Slingo, Anna Hart